• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.

作者信息

Georgakopoulos Jorge R, Yeung Jensen

机构信息

7938 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

出版信息

J Cutan Med Surg. 2020 Jul/Aug;24(4):422-423. doi: 10.1177/1203475420930223. Epub 2020 May 20.

DOI:10.1177/1203475420930223
PMID:32434413
Abstract
摘要

相似文献

1
Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.在多伦多大学两所学术医院诊所的新冠疫情期间，患者驱动的度普利尤单抗停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):422-423. doi: 10.1177/1203475420930223. Epub 2020 May 20.
2
Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.多伦多大学两所学术医院诊所中COVID-19大流行期间患者驱动的生物治疗停药率。
J Cutan Med Surg. 2020 Jul/Aug;24(4):424-425. doi: 10.1177/1203475420930226. Epub 2020 Jun 1.
3
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.在加拿大两家学术医院诊所和一家社区诊所的COVID-19大流行期间，患者驱动的阿普斯特停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
4
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.在新冠疫情期间使用度普利尤单抗治疗重度特应性皮炎成年患者的管理：一项单中心真实世界经验
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
5
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.评估在2019冠状病毒病大流行期间使用度普利尤单抗治疗特应性皮炎的风险。
J Am Acad Dermatol. 2020 Sep;83(3):e251-e252. doi: 10.1016/j.jaad.2020.06.015. Epub 2020 Jun 10.
6
COVID-19 in an elderly patient treated with secukinumab.一位接受司库奇尤单抗治疗的老年患者的新型冠状病毒肺炎
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
7
Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto.新型冠状病毒肺炎对多伦多大学两家学术医院诊所中患者主动停用奥马珠单抗的影响。
J Cutan Med Surg. 2020 Sep/Oct;24(5):534-535. doi: 10.1177/1203475420936641. Epub 2020 Jun 17.
8
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.正在接受度普利尤单抗治疗的患者出现新型冠状病毒2型无症状感染。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e368. doi: 10.1111/jdv.16619. Epub 2020 Jun 8.
9
Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.度普利尤单抗在重度特应性皮炎中的安全性及新型冠状病毒肺炎感染：两例病例报告
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303-e304. doi: 10.1111/jdv.16527. Epub 2020 Jun 8.
10
Dupilumab and COVID-19: What should we expect?度普利尤单抗与 COVID-19：我们应该期待什么？
Dermatol Ther. 2020 Jul;33(4):e13502. doi: 10.1111/dth.13502. Epub 2020 May 20.

引用本文的文献

1
Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review.度普利尤单抗在成人和青少年特应性皮炎患者中的药物生存、留存及持续性：一项叙述性文献综述
Adv Ther. 2025 Jan;42(1):94-105. doi: 10.1007/s12325-024-03052-z. Epub 2024 Nov 15.
2
Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.2019年冠状病毒病大流行对特应性皮炎和食物过敏的成人及儿童的影响：系统评价
J Allergy Clin Immunol Glob. 2023 Oct 18;3(1):100181. doi: 10.1016/j.jacig.2023.100181. eCollection 2024 Feb.
3
Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders.
儿童自身免疫性疾病患者的 2019 年冠状病毒病（COVID-19）。
Eur J Pediatr. 2023 Jul;182(7):2967-2988. doi: 10.1007/s00431-023-04958-6. Epub 2023 Apr 19.
4
Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review.COVID-19 大流行对慢性病治疗依从性的影响：系统评价。
Int J Environ Res Public Health. 2023 Feb 21;20(5):3825. doi: 10.3390/ijerph20053825.
5
Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.特应性皮炎患者在 COVID-19 感染期间使用度普利尤单抗治疗是安全的：一项对 1611 例患者的系统评价和荟萃分析。
Dermatol Ther. 2022 Jun;35(6):e15476. doi: 10.1111/dth.15476. Epub 2022 Apr 7.
6
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review.使用度普利尤单抗治疗的特应性皮炎患者中的COVID-19：三例病例及文献综述
Clin Cosmet Investig Dermatol. 2021 Aug 27;14:1131-1138. doi: 10.2147/CCID.S321003. eCollection 2021.
7
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
8
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.